Table 2. Trends in the resistance rates to anti-tuberculosis drugs among patients diagnosed with pulmonary and extrapulmonary tuberculosis from 2006 to 2013.
MDR, multidrug-resistance; XDR, extensively drug-resistance; PAS, para-aminosalicylic acid.
aAmikacin sensitivity testing at the Korean Institute of Tuberculosis (KIT) began in October 2007.
bLevofloxacin sensitivity testing at the KIT began in 2008, as gatifloxacin was removed from many markets because of the dysglycemia risk in elderly subjects.